Wave Life Sci­ences to re­ceive $170M up­front in new part­ner­ship with GSK to de­vel­op a large num­ber of can­di­dates

Wave Life Sci­ences has picked up an­oth­er deal with a ma­jor phar­ma com­pa­ny.

The Mass­a­chu­setts-based biotech on Tues­day an­nounced it has en­tered a strate­gic col­lab­o­ra­tion with GSK to ad­vance oligonu­cleotide ther­a­peu­tics. This in­cludes mov­ing along Wave’s RNA edit­ing pro­gram that tar­gets al­pha-1 an­tit­rypsin de­fi­cien­cy, dubbed WVE-006, which af­fects both the lungs and liv­er with lim­it­ed treat­ment op­tions.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN